Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624192 · ClinicalTrials.gov registry record · NA
RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years
A NA study, sponsored by Avita Medical.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03624192 is a NA study that was terminated before completion, run by Avita Medical. The registered enrollment target is 3 participants.
The verdict
NCT03624192, a NA study, was terminated before completion, sponsored by Avita Medical.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
To evaluate whether the time to complete closure is superior for RECELL-treated split-thickness donor sites, compared with Control (standardized dressings only). The mean time for donor site healing will be compared between treatments.
Interventions
- DEVICE RECELL® Autologous Cell Harvesting Device
- OTHER Telfa™ Clear and Xeroform™ dressings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2020-01-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03624192
The ClinicalTrials.gov registry entry for NCT03624192 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avita Medical, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RECELL® Autologous Cell Harvesting Device is the first listed.
NCT03624192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03624192 about?
NCT03624192 is a clinical study titled "RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years". To evaluate whether the time to complete closure is superior for RECELL-treated split-thickness donor sites, compared with Control (standardized dressings only). The mean time for donor site healing will be compared between treatments.
What is the current status of trial NCT03624192?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2018-09-19. Estimated completion is 2020-01-13.
What interventions are being tested in trial NCT03624192?
The interventions under investigation include: RECELL® Autologous Cell Harvesting Device (DEVICE), Telfa™ Clear and Xeroform™ dressings (OTHER).
Who is sponsoring clinical trial NCT03624192?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.